Opportunity Overview
Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027.
Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.
Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026.
Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract.
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.
Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026.
Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract.
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
This is one of 124 active United States Pharmaceuticals opportunities most of your competitors will never see.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | DLA Troop Support |
|---|---|
| Country | United States |
| Category | Pharmaceuticals |
| Estimated value | $17.6M |
| NAICS | 325412 |
| PSC | 6505 |
| Published | January 27, 2026 |
| Procurement stage | Request for Proposal (RFP) |
| Response due | February 15, 2028 |
| Status | Open — accepting responses |
| Official source | View original notice |
| Last verified | August 09, 2026 |
Source: U.S. Government (SAM.gov) — public domain. GlobalGov is not affiliated with or endorsed by the United States Government.
Related Opportunities in United States
See every United States Pharmaceuticals opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free United States Pharmaceuticals intelligence report in your inbox
A personalized report on United States Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.